|
1
|
Rudolf F, Joaquim LC, Vieira C,
Bjerregaard-Andersen M, Andersen A, Erlandsen M, Sodemann M,
Andersen PL and Wejse C: The Bandim tuberculosis score: Reliability
and comparison with the Karnofsky performance score. Scand J Infect
Dis. 45:256–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kosary CL: FIGO stage, histology,
histologic grade, age and race as prognostic factors in determining
survival for cancers of the female gynecological system: An
analysis of 1973-87 SEER cases of cancers of the endometrium,
cervix, ovary, vulva, and vagina. Semin Surg Oncol. 10:31–46. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poveda A: Advanced ovarian cancer: Update,
remarks and conclusions on optimal therapy. Int J Gynecol Cancer.
10:57–60. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stuart G, Avall-Lundqvist E, du Bois A,
Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E,
Friedlaender M, et al: 3rd international ovarian cancer consensus
conference: Outstanding issues for future consideration. Ann Oncol.
8 Suppl 16:viii36–viii38. 2005.
|
|
5
|
Ozols RF: Treatment goals in ovarian
cancer. Int J Gynecol Cancer. 1 Suppl 15:S3–S11. 2005. View Article : Google Scholar
|
|
6
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 6th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 1 Suppl
95:S161–S192. 2006. View Article : Google Scholar
|
|
7
|
Ozols RF: Update on gynecologic oncology
group (GOG) trials in ovarian cancer. Cancer Invest. 2 Suppl
22:S11–S20. 2004. View Article : Google Scholar
|
|
8
|
Du XL, Jiang T, Sheng XG, Li QS, Wang C
and Yu H: PET/CT scanning guided intensity-modulated radiotherapy
in treatment of recurrent ovarian cancer. Eur J Radiol.
81:3551–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang S, Dang Y, Li F, Wei W, Ma Y, Qiao S
and Wang Q: Biological intensity-modulated radiotherapy plus
neoadjuvant chemotherapy for multiple peritoneal metastases of
ovarian cancer: A case report. Oncol Lett. 9:1239–1243. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deng J, Zhang R, Pan Y, Wang B, Wu L, Jiao
X, Bao T, Hao X and Liang H: Comparison of the staging of regional
lymph nodes using the sixth and seventh editions of the
tumor-node-metastasis (TNM) classification system for the
evaluation of overall survival in gastric cancer patients: Findings
of a case-control analysis involving a single institution in China.
Surgery. 156:64–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lindner H, Willich H and Atzinger A:
Primary adjuvant whole abdominal irradiation in ovarian carcinoma.
Int J Radiat Oncol Biol Phys. 19:1203–1206. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sorbe B and Swedish-Norgewian Ovarian
Cancer Study Group: Consolidation treatment of advanced (FIGO stage
III) ovarian carcinoma in complete surgical remission after
induction chemotherapy: A randomized, controlled, clinical trial
comparing whole abdominal radiotherapy, chemotherapy, and no
further treatment. Int J Gynecol Cancer. 13:278–286. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mundt AJ, Lujan AE, Rotmensch J, Waggoner
SE, Yamada SD, Fleming G and Roeske JC: Intensity-modulated whole
pelvic radiotherapy in women with gynecologic malignancies. Int J
Radiat Oncol Biol Phys. 52:1330–1337. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Meerleer G, Vandecasteele K, Ost P,
Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den
Broecke R, Fonteyne V and De Neve W: Whole abdominopelvic
radiotherapy using intensity-modulated arc therapy in the
palliative treatment of chemotherapy-resistant ovarian cancer with
bulky peritoneal disease: A single-institution experience. Int J
Radiat Oncol Biol Phys. 79:775–781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rochet N, Jensen AD, Sterzing F, Munter
MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J and Harms W:
Adjuvant whole abdominal intensity modulated radiotherapy (IMRT)
for high risk stage FIGO III patients with ovarian cancer
(OVAR-IMRT-01)- Pilot trial of a phase I/II study: Study protocol.
BMC Cancer. 7:2272007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rochet N, Kieser M, Sterzing F, Krause S,
Lindel K, Harms W, Eichbaum MH, Schneeweiss A, Sohn C and Debus J:
Phase II study evaluating consolidation whole abdominal
intensity-modulated radiotherapy (IMRT) in patients with advanced
ovarian cancer stage FIGO III-The OVAR-IMRT-02 Study. BMC Cancer.
11:412011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rochet N, Lindel K, Katayama S, Schubert
K, Herfarth K, Schneeweiss A, Sohn C, Harms W and Debus J:
Intensity-modulated whole abdomen irradiation following adjuvant
carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer:
Four-year outcomes. Strahlenther Onkol. 191:582–589. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown AP, Jhingran A, Klopp AH, Schmeler
KM, Ramirez PT and Eifel PJ: Involved-field radiation therapy for
locoregionally recurrent ovarian cancer. Gynecol Oncol.
130:300–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chundury A, Apicelli A, DeWees T, Powell
M, Mutch D, Thaker P, Robinson C, Grigsby PW and Schwarz JK:
Intensity modulated radiation therapy for recurrent ovarian cancer
refractory to chemotherapy. Gynecol Oncol. 141:134–139. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dembo AJ, Bush RS, Beal FA, Bean HA,
Pringle JF and Sturgeon JF: The princess margaret hospital study of
ovarian cancer: Stage I, II and asymptomatic III presentations.
Cancer Treat Rep. 63:249–254. 1979.PubMed/NCBI
|
|
21
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010.
View Article : Google Scholar : PubMed/NCBI
|
